Inhibrx Says Based On FDA Discussions, There Is Potential To Pursue Accelerated Approval For INBRX-101
SAN DIEGO, Oct. 4, 2022 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that, based on
KalVista Pharmaceuticals Announces Termination Of KVD824 Phase 2 KOMPLETE Trial For Prophylactic Treatment Of Hereditary Angioedema
- Safety signals observed will not yield targeted product profile –
- No impact on Sebetralstat expected safety profile or Phase 3 KONFIDENT trial –
- Oral Factor XIIa program to become primary
The European Commission Authorized the Conversion of the Conditional Marketing Authorization for Moderna’s Spikevax to Standard Marketing Authorization
https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/covid-19-latest-updates
Connect Biopharma To Host A Conference Call Tuesday, October 4 To Discuss Topline Results For The Pivotal Trial In China Of Lead Candidate, CBP-201, In Patients With Moderate-To-Severe Atopic Dermatitis
Conference call and webcast to take place at 5:30 a.m. PDT/8:30 a.m. EDT,
tomorrow, Tuesday, October 4
SAN DIEGO and TAICANG, SUZHOU, China, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited
Theratechnologies’ Trogarzo Approved By FDA For 30-Second Intravenous (IV) Push, Simplifying HIV Treatment For Heavily Treatment-Experienced Population
Reduces maintenance dose from a 15-minute IV infusion to a 30-second, undiluted IV push every two weeks
Safety profile of Trogarzo® IV push similar to that of IV infusion
New method of
New Studies Validating The Uniqueness Of The BVA-100 Blood Test For Heart Failure Patients Compared To Pressure Measures; Shows 85% Reduction In One-Year Mortality For Medicare Heart Failure Patients With BVA-Guided Care
Patient One-Year Mortality Rate 5.6% with BVA-Guided Care Compared to 36.8% in Control Group -
Data Presented at Key Scientific Meeting
Oak Ridge, TN, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Daxor
Soleno Therapeutics Announces Initiation Of Randomized Withdrawal Study Of DCCR For Treatment Of Prader-Willi Syndrome
Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has initiated a
Enanta Pharmaceuticals Initiates A Phase 2b Clinical Study Of EDP-938 In High-Risk Adults With Respiratory Syncytial Virus
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the initiation of a Phase 2b,